RMTINasdaqPharmaceutical PreparationsFiscal year ends December 31

ROCKWELL MEDICAL, INC.

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 13, 2026

$7.49+0.06 (+0.81%)

Close on Oct 19, 2026

Market cap: $29.65M
P/E (TTM): –
Dividend yield: –

ROCKWELL MEDICAL, INC. income statement

Annual Quarterly TTM

Millions of USD, except per-share data. Shares in millions.

Line item	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31	FY 2020 2020-12-31	FY 2019 2019-12-31	FY 2018 2018-12-31	FY 2017 2017-12-31	FY 2016 2016-12-31	FY 2015 2015-12-31	FY 2014 2014-12-31	FY 2013 2013-12-31	FY 2012 2012-12-31	FY 2011 2011-12-31	FY 2010 2010-12-31	FY 2009 2009-12-31
Revenue	69	101	84	73	62	62	61	63	57	53	55	54	52	50	49	60	55
Cost of Revenue	58	84	75	69	64	59	58	65	54	47	46	46	46	43	43	50	47
Gross Profit	12	17	8.70	4.08	-2.42	2.73	2.84	-1.58	3.70	6.75	8.94	8.55	6.66	6.69	5.64	9.86	7.89
Research & Development	0	0.02	1.11	3.12	6.84	7.09	6.89	5.64	6.32	5.84	4.96	7.78	39	48	18	3.42	6.45
Selling, General & Admin	16	17	14	18	21	24	30	23	23	21	19	18	14	13	9.52	9.31	6.91
Selling & Marketing	2.35	2.75	2.13	2.09	5.73	7.87	9.05	1.00	–	–	–	–	–	–	–	–	–
General & Administrative	14	14	12	16	15	16	21	22	–	–	–	–	–	–	–	–	–
Operating Income	-4.69	0.61	-6.67	-17	-30	-28	-35	-32	-26	-20	-15	-18	-47	-54	-22	-2.87	-5.48
Interest Expense	1.12	1.25	2.30	1.94	2.36	1.88	0.03	–	–	–	–	–	–	–	–	–	–
Interest & Investment Income	–	–	0.21	0.03	0.02	0.24	0.39	–	–	0.81	0.68	0.39	0.10	0.24	0.24	0.20	0.01
Other Non-Operating Income	-0.62	-1.09	-1.77	-1.90	-2.34	-2.47	0.40	0.31	0.00	–	–	–	–	–	–	–	–
Merger & Restructuring Charges	1.00	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Asset Impairment Charges	0	0	0	0	0	0	0	0	0	–	0	0	0	0	0	–	–
Gain (Loss) on Investments	–	–	–	–	–	–	–	-0.22	-0.79	-0.03	-0.06	0.00	–	0.07	–	–	–
Gain (Loss) on Sale of Assets	-0.06	0	0.00	0.00	-0.01	-0.01	-0.01	0.00	-0.01	-0.01	-0.01	-0.01	-0.02	-0.02	-0.03	-0.02	-0.04
Legal Settlements	–	–	–	–	–	0	-0.43	-1.03	–	–	–	–	–	–	–	–	–
Pretax Income	-5.31	-0.48	-8.44	–	–	–	–	–	-26	-19	-14	-21	-49	-54	-21	-2.68	-5.50
Income Tax Expense	0	0	0	0	0	0	0	0	0	0.40	0	0	0	0	0.00	0	–
Net Income	-5.31	-0.48	-8.44	-19	-33	-31	-34	-32	-26	-20	-14	-21	-49	-54	-21	-2.68	-5.50
Net Income to Common	-5.47	-0.78	-8.59	-19	–	–	–	–	–	–	–	–	–	–	–	–	–
EPS (Basic)(per share)	-1.50	-0.30	-3.70	-13.10	-38.30	-45.10	-61.60	-67.10	-56.10	-42.90	-31.90	-57.20	-162.80	-291.50	-133.10	-17.60	-40.70
EPS (Diluted)(per share)	-1.50	-0.30	-3.70	-13.10	-38.30	-45.10	-61.60	-67.10	-56.10	-42.90	-31.90	-57.20	-162.80	-291.50	-133.10	-17.60	-40.70
Shares Outstanding (Basic, Weighted)(shares)	3.60	3.11	2.33	1.43	0.85	0.69	0.55	0.48	0.46	0.46	0.46	0.38	0.30	0.19	0.16	0.16	–
Shares Outstanding (Diluted, Weighted)(shares)	3.60	3.11	2.33	1.43	0.85	0.69	0.55	0.48	0.46	0.46	0.46	0.38	0.30	0.19	0.16	0.16	–
EBITDA	-2.50	2.79	-5.23	-16	-30	-28	-34	-32	-25	-19	-14	-17	-46	-53	-21	-1.48	-4.25
Net Interest Income	–	–	–	–	–	–	0.37	0.54	0.79	–	–	-4.15	-1.82	0.00	0.00	-0.01	-0.03

Italic numbers are calculated by StockData (for example Q4 = full year − nine months). Per-share data and share counts are adjusted for stock splits. Hover a number for its source; click it to open the filing on SEC.gov. Click a row to chart it.

Ratios

Latest available, balances at Jun 30, 2026

Profitability, TTM

Gross margin: 17.7%
Operating margin: -6.5%
Net margin: -7.3%
Return on equity, FY2025: -15.3%

Financial strength

Current ratio: 3.25
Debt to equity: 0.26
Debt to assets: 15.9%
Cash to current liabilities: 94.1%

Valuation

P/E ratio: –
Price to sales: 0.43
Price to book: 0.85
Dividend yield: –